Method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of Hepatitis C Virus for genotypes 1 to 6, more in particular for subtype specific genotypes 1 a, 1 b, 2a, 2b, 3a, 4a and 4d, present in a sample comprising: a) obtaining said sample from a patient, b) extracting viral genetic material from said sample, c) amplification of the NS5B region of HCV to generate a DNA amplicon of 388 base pairs by using primers having the sequences selected from the group consisting of SEQ ID NO's 1-5, d) sequencing of the amplicon to obtain a sequence of 329 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 3-5, e) performing phylogenetic tree analysis using the 329 base pair sequence, information of NS5B to obtain HCV-subtype information in said patient sample, f 1) using subtype-specific primers having the sequences selected from either the group consisting of SEQ ID NO's 6-9, 42-45, 104-107, 120-123, 145-148 or 180-183 for the generation of a DNA amplicon comprising the non-structural protein NS3 (N-terminal 181 amino acids), g 1) sequencing the NS3 amplicon to obtain a sequence of 543 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 8 and 9; 43 and 45-46; 104 and 106; 120 and 122; 146 and 148 or 180 and 182 or f 2) using subtype-specific primers having the sequences selected from the group consisting of SEQ ID NO's 13-16, 54 and 59-66,, 124- 133, 158 and 160-168 or 194-197 for the generation of a DNA amplicon comprising NS5B polymerase, g 2) sequencing the NS5B polymerase amplicon to obtain a sequence of 1776 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 15-16 and 87-92; 54, 59 and 61-66; 124 and 127-133; 158-159, 161 and 163-168 or 197-204 or f 3) using subtype-specific primers having the sequences selected from the group consisting of SEQ ID NO's 30-33, 67-70, 93-96, 108-111, 134-137 or 169-172 for the generation of a DNA amplicon comprising NS3 / 4A, g 3) sequencing the NS3/4A protease amplicon to obtain a sequence of 2055 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 34-41; 68 and 71-77; 95 and 97-103; 112-119; 136 and 138-144 or 171 and 173-179 or f 4) using subtype-specific primers having the sequences selected from the group consisting of SEQ ID NO's 47-50, 78-81, 149-151 and 159 or 184-187 for the generation of a DNA amplicon comprising NS4B / 5A, g 4) sequencing the NS4B/5A amplicon to obtain a sequence of the two genes NS4B and NS5A by using the sequences selected from the group consisting of SEQ ID NO's 51-57; 79 and 81-87; 152-159 or 185 and 187-193; h) aligning the sequence obtained in step (g 1),, (g 3) or (g 4) with a reference or wild-type HCV sequence, i) determining drug resistance mutation(s) in the viral genetic material present in patient sample. a) obtaining said sample from a patient, b) extracting viral genetic material from said sample, c) amplification of the NS5B region of HCV to generate a DNA amplicon of 388 base pairs by using primers having the sequences selected from the group consisting of SEQ ID NO's 1-5, d) sequencing of the amplicon to obtain a sequence of 329 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 3-5, e) performing phylogenetic tree analysis using the 329 base pair sequence, information of NS5B to obtain HCV-subtype information in said patient sample, f 1) using subtype-specific primers having the sequences selected from either the group consisting of SEQ ID NO's 6-9, 42-45, 104-107, 120-123, 145-148 or 180-183 for the generation of a DNA amplicon comprising the non-structural protein NS3 (N-terminal 181 amino acids), g 1) sequencing the NS3 amplicon to obtain a sequence of 543 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 8 and 9; 43 and 45-46; 104 and 106; 120 and 122; 146 and 148 or 180 and 182 or f 2) using subtype-specific primers having the sequences selected from the group consisting of SEQ ID NO's 13-16, 54 and 59-66,, 124- 133, 158 and 160-168 or 194-197 for the generation of a DNA amplicon comprising NS5B polymerase, g 2) sequencing the NS5B polymerase amplicon to obtain a sequence of 1776 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 15-16 and 87-92; 54, 59 and 61-66; 124 and 127-133; 158-159, 161 and 163-168 or 197-204 or f 3) using subtype-specific primers having the sequences selected from the group consisting of SEQ ID NO's 30-33, 67-70, 93-96, 108-111, 134-137 or 169-172 for the generation of a DNA amplicon comprising NS3 / 4A, g 3) sequencing the NS3/4A protease amplicon to obtain a sequence of 2055 base pairs by using the sequences selected from the group consisting of SEQ ID NO's 34-41; 68 and 71-77; 95 and 97-103; 112-119; 136 and 138-144 or 171 and 173-179 or f 4) using subtype-specific primers having the sequences selected from the group consisting of SEQ ID NO's 47-50, 78-81, 149-151 and 159 or 184-187 for the generation of a DNA amplicon comprising NS4B / 5A, g 4) sequencing the NS4B/5A amplicon to obtain a sequence of the two genes NS4B and NS5A by using the sequences selected from the group consisting of SEQ ID NO's 51-57; 79 and 81-87; 152-159 or 185 and 187-193; h) aligning the sequence obtained in step (g 1),, (g 3) or (g 4) with a reference or wild-type HCV sequence, i) determining drug resistance mutation(s) in the viral genetic material present in patient sample.